Skip to main content
EIV Diagnostics
EIV Diagnostics
اپائنٹمنٹ بک کریں

By EIV Diagnostics · September 11, 2026

Clinicians: 2–4 Minute ROSE Passes for Molecular Triage, Telecytology

Practical ROSE workflow for clinicians and trainees: make each pass 2–4 minutes, prioritize molecular triage, and validate telecytology for reliable...

Clinicians: 2–4 Minute ROSE Passes for Molecular Triage, Telecytology

Rapid onsite evaluation (ROSE) is a real-time cytologic adequacy and triage assessment performed during biopsy procedures to confirm sample sufficiency and allocate material for downstream testing. The main payoff is fewer repeat procedures and smarter use of limited tissue. A cytopathologist, cytotechnologist, or trained clinician reviews a stained smear within minutes of needle passage, then directs the rest of the case in real time.

TL;DR:

  • ROSE improves sample adequacy rates, reducing the need for repeat procedures and enabling better allocation of limited tissue for ancillary tests.
  • It is most effective when performed by trained professionals such as pathologists, trainees, or cytotechnologists, with billing contingent on specific CPT codes and supervision rules.
  • Setting up an efficient ROSE service requires portable equipment, rapid staining with Diff-Quik, and rehearsed workflows to keep evaluation time within two to four minutes per pass.
  • Proper triage of tissue passes based on clinical suspicion and biopsy type maximizes limited material for tests like molecular panels or flow cytometry.
  • Telecytology can support remote ROSE, but validation and quality checks are essential, with onsite review generally preferable for ambiguous or low-cellularity samples.
EIV Diagnostics
Support for Complex Diagnostic Workflows
EIV Diagnostics provides molecular pathology, digital pathology, and pathology services for healthcare providers managing complex diagnostic needs.
Visit EIV Diagnostics

Table of Contents

What Is Rapid Onsite Evaluation Used For in Clinical Practice?

ROSE exists because modern diagnostics ask more of smaller and smaller samples. A single fine-needle aspiration might need to yield a diagnosis, a subtype call, and enough intact cells for a gene panel. Without someone reading slides chairside, a proceduralist has no way to know whether they’ve collected enough material until pathology reports back hours or days later, often after the patient has gone home.

That’s the gap ROSE closes. A pathologist or cytotechnologist stationed at the bedside or in the procedure suite reviews a stained smear or touch preparation within minutes and tells the team whether to keep sampling, stop, or redirect the needle.

ROSE shows up most often in:

  • Fine-needle aspiration (FNA) of thyroid, salivary gland, lymph node, and superficial soft tissue masses
  • Endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) for mediastinal and hilar lymph node staging
  • CT-guided percutaneous biopsies of lung, liver, pancreas, and retroperitoneal lesions
  • Endoscopic ultrasound-guided FNA (EUS-FNA) of pancreatic masses and adjacent structures

The clinical logic is straightforward: a biopsy with ROSE uses real-time assessment to confirm specimen adequacy, triage material for ancillary tests, and optimize the procedure itself, rather than leaving that judgment to chance. Meta-analyses and single-center studies report meaningfully higher adequacy rates with ROSE compared with non-ROSE approaches across thyroid and lung FNA settings. For a busy interventional radiology or pulmonology service, that translates into fewer callbacks, fewer repeat sedations, and a shorter runway to a treatment decision.

Who Performs Rapid Onsite Evaluation and What Are the Role Boundaries?

Three types of professionals typically staff a ROSE service, and their scope varies by institution and by payer rules.

A board-certified pathologist can render an independent preliminary diagnosis and bill for it. A pathology trainee usually works under direct or indirect supervision, reviewing slides and presenting findings before an attending confirms the call. A cytotechnologist assesses adequacy (cellular versus scant versus nondiagnostic) but generally defers definitive diagnostic impressions, like calling a lesion malignant, to the supervising pathologist. Some institutions also train advanced practice clinicians or specially credentialed nurses to perform basic adequacy checks, though this remains less common outside high-volume academic centers.

Billing adds a layer clinicians should know before assuming ROSE is automatically reimbursable. Certain CPT codes tied to immediate interpretation require attending pathologist involvement to bill correctly, so a cytotechnologist-only assessment may not support the same code a pathologist-reviewed case would.

Practical escalation rules matter as much as titles:

  • Stop sampling once two to three consecutive passes show consistent, diagnostic cellularity
  • Request an additional pass if the smear is bloody, hypocellular, or shows only necrotic debris
  • Escalate to a core biopsy when repeated FNA passes fail to yield adequate material, particularly for suspected lymphoma or when architecture-dependent diagnoses are likely

Building an Onsite Evaluation Setup That Doesn’t Slow Down the Room

A functional ROSE service runs on a portable cart, not a fixed lab bench, because the whole point is bringing the microscope to the patient rather than the reverse.

  1. Microscope with adequate objectives (10x, 20x, 40x oil optional) for rapid cellularity and morphology checks
  2. Stain line, most commonly Diff-Quik, chosen because it delivers a readable slide in under a minute compared with the longer fixation and staining cycles of Papanicolaou stains
  3. Glass slides, coverslips, and spray fixative for both air-dried and alcohol-fixed preparations
  4. RPMI transport tubes for flow cytometry candidates and formalin containers for cell block material
  5. Sharps disposal, gloves, and labeling supplies positioned within arm’s reach of the staining station

Practice guides consistently emphasize maintaining stain quality per laboratory standards, which means periodic quality checks on Diff-Quik reagents, not just restocking when a bottle runs dry. Power access and a stable, vibration-free surface matter more than teams expect.

How to Conduct Onsite Evaluations: The Step-by-Step Workflow

The mechanics of a ROSE pass follow a tight sequence, and speed only works if every step is rehearsed.

  1. Recover the sample. For FNA, the proceduralist expels the aspirate from the needle hub onto a slide using a syringe filled with air or saline. For core needle biopsies, a cytotechnologist or pathologist makes a touch preparation by gently rolling the tissue core surface against a slide, taking care not to crush the specimen needed for histology.
  2. Prepare the smear. Spread the material evenly with a second slide (the pull-smear technique) or apply a light touch prep, depending on sample viscosity.
  3. Apply single-slide assessment (SSA) when material is limited. SSA means making one representative slide per pass rather than multiple smears, which speeds review and preserves tissue for ancillary testing. Single-slide assessment techniques reduce preparation time and achieve high adequacy rates when performed correctly.
  4. Stain with Diff-Quik. The standard sequence runs through a fixative dip, then eosinophilic and basophilic solutions, each for a matter of seconds, followed by a water rinse. A trained cytotechnologist can complete this in under 60 seconds per slide.
  5. Review under the microscope. Scan at low power for cellularity and architecture, then move to higher power to confirm cell type and rule out obscuring blood or necrosis.
  6. Communicate adequacy immediately. State a clear verdict to the proceduralist: adequate, nondiagnostic, or “one more pass needed, target the posterior margin.” Vague feedback wastes the very time ROSE is meant to save.

Pro Tip: Keep a running mental tally of which pass went to cytology, which to cell block, and which to a needle rinse for flow cytometry. Announcing the allocation out loud as each pass comes in prevents the last, most cellular pass from accidentally being wasted on a repeat smear.

Each pass typically takes two to four minutes from slide preparation to verbal feedback once a team has done this together for a few months. Institutions that fall short of that pace usually have a staining bottleneck, not a review bottleneck.

Adequacy Categories and Billing Codes You Need to Know

Most ROSE services report findings using a short, standardized vocabulary rather than a full diagnostic narrative. Typical categories include:

  • Nondiagnostic — insufficient cellular material to render an opinion
  • Adequate — sufficient material present, no definitive interpretation yet offered
  • Atypical — cells present with uncertain features, warranting further workup
  • Suspicious — findings favor malignancy but fall short of a definitive call
  • Malignant — diagnostic material for malignancy identified onsite

A preliminary ROSE report should record the category, the pass number it applies to, and any triage instructions given, since those notes become part of the medical record and inform the final cytopathology report.

CPT coding follows the specimen type. Smears prepared and interpreted onsite typically fall under 88172 (immediate cytohistologic study, first evaluation episode) and 88177 (each additional evaluation episode), while touch preparations from core biopsies often use 88333 (initial) and 88334 (each additional block). Reimbursement rules vary by payer, and as noted earlier, some payers restrict 88172/88177 billing to cases with attending pathologist interpretation, so verify local coverage policies before assuming a cytotechnologist-led case bills the same way a pathologist-led one does.

Triage Strategy: Making Limited Material Count

Every ROSE case is an exercise in prioritization. You rarely get unlimited passes, and once tissue is gone, it’s gone.

The allocation decision hinges on three factors: the clinical question (is this a staging biopsy or a new mass workup?), the pretest imaging suspicion, and how many passes the patient’s clinical status allows. ROSE improves specimen adequacy and allows partitioning of limited aspirate material across cell blocks, immunohistochemistry, flow cytometry, microbiology, and molecular studies. It often completes a full diagnostic workup from a single encounter.

Common triage patterns include:

  • Lung nodule, suspected adenocarcinoma: reserve at least one pass exclusively for cell block, since immunohistochemistry and molecular panels (EGFR, ALK, ROS1, PD-L1) all draw from that block
  • Lung nodule, suspected small cell carcinoma: prioritize smears for rapid morphologic confirmation before committing remaining material to cell block, since small cell histology is often diagnostic on cytology alone
  • Suspected lymphoma in a lymph node: send a fresh needle rinse in RPMI for flow cytometry before anything else, since flow cytometry requires viable cells
  • Thyroid nodule: prioritize smears for Bethesda categorization, then reserve any surplus for molecular testing if cytology is indeterminate

Fixation choice affects nucleic acid quality. Air-dried, alcohol-fixed material generally preserves DNA better for downstream PCR-based assays than prolonged formalin exposure, which is why the ROSE team’s real-time allocation call happens before fixation, not after.

When Telecytology Can Substitute for Onsite Presence

Not every procedure site has a cytopathologist standing by, and telecytology has closed part of that gap. Telecytology can support remote ROSE following appropriate validation, though each model carries its own technical tradeoffs.

  • Live-stream microscopy, where a remote pathologist views real-time video through a robotic or remote-controlled microscope, most closely mimics in-person review but depends on stable bandwidth
  • Static image capture, where the onsite technologist selects and transmits representative fields, is simpler to deploy but risks missing diagnostic cells outside the captured frame
  • Whole-slide digital capture offers the most complete record for later review but introduces latency that can be a problem for time-sensitive adequacy calls

Each model requires its own validation study comparing remote calls against in-person ground truth before going live, plus ongoing quality checks. EIV Diagnostics’s digital pathology capabilities reflect the same underlying principle: remote review only works when the imaging pipeline and the reviewing pathologist’s judgment are both proven reliable. Onsite presence still tends to win out for hypocellular or ambiguous samples, where a remote reviewer can’t easily request a different focal plane or ask the technologist to reprepare a slide on the spot.

Benefits and Limitations: What the Evidence Actually Shows

ROSE’s advantages are well documented, but they aren’t free.

What works: improved specimen adequacy, fewer repeat invasive procedures, and better-optimized ancillary testing top the list. Systematic and single-center evidence supports meaningfully higher adequacy rates with ROSE across several biopsy types, including thyroid and lung.

What doesn’t come free: ROSE’s accuracy depends heavily on the experience of whoever is reading the slide. A cytotechnologist or trainee with limited exposure can misjudge borderline cellularity, occasionally giving an equivocal “adequate” call on material that later proves nondiagnostic on final review. Compensation and staffing costs also matter. Someone has to be available, on call, for every relevant procedure block, and that person’s time isn’t free even when a case turns out routine.

Institutions weighing whether to build a ROSE service should treat it as a staffing and workflow investment first, and a diagnostic add-on second.

Getting More From Every Pass: Field-Tested Troubleshooting

A few habits separate a smooth ROSE service from one that constantly runs behind.

Pro Tip: When a pass comes back blood-stained rather than cellular, don’t automatically ask for another full pass. First try reducing suction pressure on the next attempt, since excessive suction is a common cause of blood dilution masking adequate cellular yield.

  • Log every suction or needle-gauge adjustment in the procedure note, along with the rationale, so the next pass builds on what was just learned
  • When making touch preparations from a core biopsy, roll gently rather than pressing, to avoid depleting the tissue histology needs
  • Label each slide and tube the moment it’s produced, not after the case, since post-procedure labeling is a common source of specimen mix-ups
  • Stop sampling once cellularity is confirmed rather than chasing a “perfect” pass, which only depletes tissue that could go to ancillary testing

How EIV Diagnostics Supports Rapid Onsite Evaluation Workflows

A ROSE call onsite is only half the equation. What happens to that material afterward, how fast it reaches molecular testing, and how reliably it gets reported back, determines whether the effort at the bedside actually shortens a patient’s path to treatment.

EIV Diagnostics operates as an independent pathology laboratory offering molecular pathology, digital pathology, and cell block processing support for practices running ROSE-guided procedures. Board-certified pathologists review submitted material and report findings with attention to turnaround time, which matters most when a triage decision made at the bedside needs confirmation before a treatment plan can move forward. For practices that need sample collection without an in-house draw station, EIV Diagnostics also offers mobile phlebotomy services that bring collection directly to a clinic or patient location.

A Pragmatic Rollout Checklist for Practices Starting ROSE

Start small: pilot ROSE on one high-volume procedure type, thyroid FNA or EBUS-TBNA are common choices, before expanding. Train staff on Diff-Quik staining and single-slide assessment together, not separately. Confirm CPT billing eligibility with your payer before scheduling a full slate. Add telecytology only after your in-person adequacy rates are stable and documented.

— EIV Diagnostics

How EIV Diagnostics Can Partner With Your Practice

Getting a ROSE-guided sample from the procedure room to a final, actionable report is where most practices lose time, not in the biopsy itself. Some laboratories give referring clinicians a direct path around that bottleneck: submitted specimens go to board-certified pathologists who prioritize turnaround on molecular and cell block workups, so a triage call made chairside doesn’t sit in a queue for a week before it means anything clinically.

EIV Diagnostics

Whether your team needs molecular pathology support to complete an EGFR or ALK panel from a limited FNA pass, or digital pathology review for a case that needs a second opinion fast, EIV Diagnostics handles the downstream work so your ROSE service delivers on its promise. Practices managing high procedure volume may also find value in resources like this medical phone triage guide for keeping scheduling and callback workflows tight around biopsy days. To set up a referral pathway or ask about turnaround times for your specimen types, reach out through EIV Diagnostics’s services page and a team member will walk you through what submission looks like for your practice.

Sources

This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.

FAQ

Is a Cytology Test Like FNA Painful?

Cytology tests including fine-needle aspiration are generally less painful and less invasive than core tissue biopsies, with most patients reporting only brief discomfort during the needle pass. Serious complications are rare.

What Is a Biopsy With ROSE?

A biopsy with ROSE means a pathologist or cytotechnologist reviews stained smears at the bedside during the procedure, confirming adequacy in real time and directing whether more passes are needed. This differs from a standard biopsy, where adequacy isn’t known until the specimen reaches the lab.

What Do Cytology Test Results Indicate?

Cytology results typically fall into categories like nondiagnostic, atypical, suspicious, or malignant, describing the cellular findings without necessarily providing a final histologic diagnosis. A cytopathology report guides whether further tissue sampling or treatment planning is warranted.

What Is the Purpose of Cytology Evaluation?

Cytology evaluation examines individual cells or small cell clusters to detect abnormalities, infections, or malignancy, often as a first-line, less invasive alternative to tissue biopsy. When performed onsite during a procedure, it also serves the added purpose of confirming enough material has been collected before the patient leaves the room.

Who Is Qualified to Perform Rapid Onsite Evaluation?

Board-certified pathologists, pathology trainees under supervision, and trained cytotechnologists can all perform ROSE, though certain billing codes require attending pathologist interpretation to be reimbursable. Facilities partnering with a laboratory like EIV Diagnostics can route ambiguous or complex cases for confirmatory pathologist review after the onsite call.

← Back to all articles